PER

Education doesn’t stop. And neither do we. 2026 is all about: 🌎Global conversations 📍Iconic destinations 💡Real-world impact Together, we can turn collective knowledge into clinical impact, redefining the standard of patient care. Be part of it at gotoPER.com.

Excited to kick off our inaugural “Fred Hutch and Friends” meeting! Outstanding participation from both academic and community oncology practices. This year’s theme is Immunotherapy, with the goal of bringing academic and community partners together to advance collaboration, education, and patient care. @fredhutch #FredHutchandFriends @gotoPER @PGrivasMDPhD

Bispecific Antibodies In Lymphoma and Multiple Myeloma: Operational Lessons and Collaborative Strategies (Spotlight CE Session) x.com/i/broadcasts/1…

Recent Advances in the Treatment of Relapsed Refractory Follicular Lymphoma x.com/i/broadcasts/1…

Recent Advances in the Treatment of Relapsed Refractory Follicular Lymphoma x.com/i/broadcasts/1…

The #ESMOBreast2026 oral SERD findings raise important questions & that’s exactly why this conversation matters. Join us 5/27 for #OncologyTownHall Oral SERDs!🔗 lnkd.in/easu6wGf @hoperugo @hmcarthur @FAndreMD @Prof_Nadia_H #oncology #breastcancer #bcsm

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence x.com/i/broadcasts/1…

Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer (1) (1) x.com/i/broadcasts/1…

Applying the Latest Evidence for New Targeted Therapies in HER2-Positive GEA x.com/i/broadcasts/1…

🌍PER Global Perspectives: Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs, a 3-part webinar series on frontline combinations, CNS disease, & toxicity differentiation. Gain insights from global experts shaping the future of NSCLC. Register now tinyurl.com/28vdwy7z

Windy City Wednesday with PER® 🚨 The landscape of ADCs and bispecific antibodies across solid tumors is rapidly expanding—are you ready to navigate the latest targets, data, and clinical decisions? Join us to learn more! #gotoPER #windycitywednesday #ASCO26

DLL3-Directed Therapies in SCLC – A Nursing-Centered Approach to Care x.com/i/broadcasts/1…

Stay current on the mTNBC frontline treatment landscape with the @OncBrothers. Review pivotal frontline trial data, explore how PD-L1 status can guide treatment decisions, and gain practical strategies for managing treatment-related adverse events. 👉bit.ly/4tv6Hed

Behind every outcome, there’s a nurse. 💛 This #NationalNursesWeek, we recognize the nurses who are there at every step of care. Their work shapes outcomes, experiences, and hope for patients and families. Thank you, nurses, for everything you make possible. #OncologyNursing

Unlock the latest insights on KRAS as a Therapeutic Target in PDAC. Explore efficacy & safety data, learn how to apply molecular profiling results, evolving evidence, and patient-specific factors to optimize targeted treatment. Start learning now: bit.ly/4nhLlPX

This World Ovarian Cancer Day, we stand together to raise awareness, inspire action, and advance care for every patient affected. Join Co-Chair Ritu Salani, MD, MBA at the 17th Annual International Symposium on Gynecologic Malignancies tomorrow! #WorldOvarianCancerDay #IOG #CME

Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer (1) x.com/i/broadcasts/1…

Windy City Wednesday with PER! Join these expert-led sessions highlighting key advances shaping today’s breast cancer landscape and gain deeper insight into emerging clinical trial data that is driving practice-changing decisions. #gotoPER #windycitywednesday #ASCO26

Collaborative Care Symposium x.com/i/broadcasts/1…

Collaborative Care Symposium x.com/i/broadcasts/1…

Collaborative Care Symposium x.com/i/broadcasts/1…